HEMATOLOGICAL

Testing Menu

HEMATOLOGICAL

Testing Menu

Browse our comprehensive menu of product & testing services.

For additional information about our products and services, please call +1 858.224.6600 or email sales@invivoscribe.com.

Browse our comprehensive menu of product & testing services.

For additional information about our products and services, please call +1 858.224.6600 or email sales@invivoscribe.com.

Lymphoid

Hematological Testing Menu

Adult T-cell leukemia/lymphoma
Anaplastic large-cell lymphoma
Angioimmunoblastic T-cell lymphoma
Chronic lymphocytic leukemia (CLL)
Diffuse large B-cell lymphoma (DLBCL), NOS

Follicular lymphoma
Mantle cell lymphoma (MCL)
Marginal zone lymphoma
Peripheral T-cell lymphoma
Plasma cell myeloma (Multiple Myeloma)

Suspect B-cell Proliferations
T-Cell Large Granular Lymphocytic Leukemia (T-LGL Leukemia)
T-Cell Prolymphocytic Leukemia (T-PLL)

Myeloid

Hematological Testing Menu

Acute myeloid leukemia (AML) and related neoplasms
Myelodysplastic syndromes (MDS)
Myeloproliferative neoplasms (MPN)

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 1st, 2024 Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

March 1st, 2024 Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

January 25th, 2024 Leveraging Standardized MRD Assays to Guide CLL Treatment

March 23rd, 2023 Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

HEMATOLOGICAL

Testing Menu

HEMATOLOGICAL

Testing Menu

Browse our comprehensive menu of product & testing services.

Browse our comprehensive menu of product & testing services.

For additional information about our products and services, please call +1 858.224.6600 or email sales@invivoscribe.com.

Lymphoid

Hematological Testing Menu

Myeloid

Hematological Testing Menu

Title

Global Search

SEARCH BY KEYWORD

Global Search

SEARCH BY KEYWORD

Looking for Product Documents?
Try our New Document Search Feature ⟶

Looking for Product Documents?
Try our New Document Search Feature ⟶

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 1st, 2024 Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

March 1st, 2024 Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

January 25th, 2024 Leveraging Standardized MRD Assays to Guide CLL Treatment

March 23rd, 2023 Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

HEMATOLOGICAL

Testing Menu

HEMATOLOGICAL

Testing Menu

Browse our comprehensive menu of product & testing services.

Browse our comprehensive menu of product & testing services.

For additional information about our products and services, please call +1 858.224.6600 or email sales@invivoscribe.com.

Lymphoid

Hematological Testing Menu

Myeloid

Hematological Testing Menu

Title

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.